Already a member? Log in

Sign up with your...

or

Sign Up with your email address

Add Tags

Duplicate Tags

Rename Tags

Share It With Others!

Save Link

Sign in

Sign Up with your email address

Sign up

By clicking the button, you agree to the Terms & Conditions.

Forgot Password?

Please enter your username below and press the send button.
A password reset link will be sent to you.

If you are unable to access the email address originally associated with your Delicious account, we recommend creating a new account.

ADVERTISEMENT

Links 1 through 10 of 177 by NAPWHA tagged Gilead

Gilead Sciences Inc. posted a 34 percent increase in fourth-quarter profit, trouncing Wall Street expectations, as sales of its blockbuster hepatitis C drugs soared in Japan and offset lower sales in the U.S.

Share It With Others!

AIDS Healthcare Foundation has filed a lawsuit against Gilead Sciences, accusing the drugmaker of manipulating the patent system to extend the patents on its HIV drug tenofovir, which is sold under the brand name Viread and included in the combination treatments Truvada, Stribild and Genvoya.

Share It With Others!

The attorney general of Massachusetts said on Wednesday that she had opened an inquiry into whether Gilead Sciences had violated state consumer protection laws by charging too much for its hepatitis C drugs.

Share It With Others!

AIDS Healthcare Foundation (AHF) filed a federal lawsuit today against Gilead Sciences Inc. seeking to invalidate patents on key AIDS drugs held by the Bay Area drug maker.

Share It With Others!

In what looks to be the first direct-to-consumer drug advertising paid for by Gilead Sciences, Inc. for use of its AIDS treatment, Truvada, as pre-exposure prophylaxis (PrEP) to prevent HIV infection in non-infected individuals, Gilead has paid for an ad that violates Food and Drug Administration (FDA) guidelines for PrEP by promoting off-label use of the drug by encouraging situational PrEP use for those who “… like to party.”

Share It With Others!

Gilead Sciences, Inc. (NASDAQ:GILD) has announced the Food and Drug Administration’s approval of its Genvoya drug for patients being treated for HIV-1 infection. The treatment will become the first TAF-based regimen.

Share It With Others!

A triple combination of Gilead Sciences' sofosbuvir/ledipasvir (Harvoni) plus the experimental HCV protease inhibitor vedroprevir cured 96% of treatment-experienced, genotype 1 hepatitis C patients with cirrhosis, without the need for ribavirin, according to study findings presented on Tuesday at the 2015 AASLD Liver Meeting in San Francisco.

Share It With Others!

Pharmaceutical companies including Gilead Sciences Inc. and Sanofi kept secret more than a third of all clinical trial results for 15 drugs approved in 2012, according to a study, failing to publish data that could tip off doctors and patients to potentially dangerous side effects.

Share It With Others!

Gilead Sciences announced its Truvada as PrEP co-pay assistance program will cover a total annual benefit of $3,600 with no monthly limit, according to Gilead spokesperson Ryan McKeel. The new program is effective November 6.

Share It With Others!

Gilead Sciences said Thursday the U.S. Food and Drug Administration approved the biotech company’s single tablet regimen treatment for HIV-1 infection. Genvoya is the first drug with tenofovir alafenamide, or TAF, to receive FDA approval.

Share It With Others!

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT